Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
Epilepsia Open · 2023-06 · 8 (2) · 360-370
DOI: 10.1002/epi4.12699 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsia Open, online erschienen am 06.02.2023. Verfasst von Fabienne Kühne und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Charité - University Medicine Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Cannabidiol, Epilepsy, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Einstein Stiftung Berlin, GW Pharmaceuticals.
Abstract (Originalsprache)
Objective
Cannabidiol (CBD) is approved for treatment of Dravet syndrome (DS), Lennox‐Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC). Several studies suggest antiseizure effects also beyond these three epilepsy syndromes.
Methods
In a retrospective multicenter study, we analyzed the efficacy and tolerability of CBD in patients with epilepsy at 16 epilepsy centers.
Results
The study cohort comprised 311 patients with epilepsy with a median age of 11.3 (0‐72) years (235 children and adolescents, 76 adults). Therapy with CBD was off‐label in 91.3% of cases due to age, epilepsy subtype, lack of adjunct therapy with clobazam, and/or higher dose applied. CBD titration regimens were slower than recommended, with good tolerability of higher doses particularly in children. Of all patients, 36.9% experienced a reduction in seizure frequency of >50%, independent of their epilepsy subtype or clobazam co‐medication. The median observation period was 15.8 months. About one third of all patients discontinued therapy within the observation period due to adverse effects or lack of efficacy. Adverse effects were reported frequently (46.9%). Significance Our study highlights that CBD has an antiseizure effect comparable to other antiseizure medications with a positive safety profile independent of the epilepsy subtype. Comedication with clobazam was not associated with a better outcome. Higher doses to achieve seizure frequency reduction were safe, particularly in children. These findings call for further trials for an extended approval of CBD for other epilepsy subtypes and for children
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Neurology, Charité - University Medicine Berlin, Berlin, Germany.
- Charité - University Medicine Berlin, Center for Chronically Sick Children, Berlin, Germany.
- Charité - University Medicine Berlin, German Epilepsy Center for Children and Adolescents, Berlin, Germany.
- Charité - University Medicine, Institute of Cell- and Neurobiology, Berlin, Germany.
- Kork Epilepsy Center, Kehl-Kork, Germany.
- Department of Pediatric Neurology, Epilepsy Center, University Medicine Greifswald, Greifswald, Germany.
ORCID-Profile: Fabienne Kühne, Lena-Luise Becker, Thomas Bast, Astrid Bertsche, Ingo Borggraefe, Christian Malte Boßelmann, Christoph Hertzberg, Martin Hirsch, Martin Holtkamp, Holger Lerche, Konstantin L Makridis, Felix von Podewils, Susanne Schubert-Bast, Andreas Schulze-Bonhage, Bernhard J Steinhoff, Adam Strzelczyk, Steffen Syrbe, Heike De Vries, Christine Prager, Kerstin A Klotz, Angela M Kaindl
Förderung
- Einstein Stiftung Berlin
- GW Pharmaceuticals
Zitieren
APA
Kühne, F., Becker, L. L., Bast, T., Bertsche, A., Borggraefe, I., Boßelmann, C. M., Fahrbach, J., Hertzberg, C., Herz, N. A., Hirsch, M., Holtkamp, M., Janello, C., Kluger, G. J., Kurlemann, G., Lerche, H., Makridis, K. L., von Podewils, F., Pringsheim, M., Schubert-Bast, S., …, & Kaindl, A. M. (2023). Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open, 8(2), 360-370. https://doi.org/10.1002/epi4.12699
Vancouver
Kühne F, Becker LL, Bast T, Bertsche A, Borggraefe I, Boßelmann CM, et al. Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. Epilepsia Open. 2023;8(2):360-370. doi:10.1002/epi4.12699
BibTeX
@article{Khne2023,
author = {Kühne, Fabienne and Becker, Lena-Luise and Bast, Thomas and Bertsche, Astrid and Borggraefe, Ingo and Boßelmann, Christian Malte and Fahrbach, Jörg and Hertzberg, Christoph and Herz, Nina A and Hirsch, Martin and Holtkamp, Martin and Janello, Christine and Kluger, Gerhard Josef and Kurlemann, Gerhard and Lerche, Holger and Makridis, Konstantin L and von Podewils, Felix and Pringsheim, Milka and Schubert-Bast, Susanne and Schulz, Juliane and Schulze-Bonhage, Andreas and Steinbart, David and Steinhoff, Bernhard J and Strzelczyk, Adam and Syrbe, Steffen and De Vries, Heike and Wagner, Christiane and Wagner, Johanna and Wilken, Bernd and Prager, Christine and Klotz, Kerstin A and Kaindl, Angela M},
title = {Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study},
journal = {Epilepsia Open},
year = {2023},
volume = {8},
number = {2},
pages = {360--370},
doi = {10.1002/epi4.12699}
}
EUVIMED